India, Oct. 16 -- Tiziana Life Sciences, Ltd. (TLSA) announced that the last patients has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer's disease, marking the completion of enrolment and dosing initiation for all study participants.
Alzheimer's disease is a progressive neurological disorder that affects memory, thinking and daily functioning. Growing evidence suggests that persistent inflammation in the brain may contribute to disease progression, even in patients receiving currently approved anti-amyloid therapies.
Foralumab is a fully human, anti-CD3 monoclonal antibody being developed as an intranasal therapy designed to modulate immune ac...